Sonoma Pharmaceuticals, EMC Pharma roll out collaboration to co-market expanded eye care product line

(Image Credit: AdobeStock/thodonal)

Sonoma Pharmaceuticals Inc. and EMC Pharma announced they have entered into a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line.

Sonoma is developing and producing patented Microcyntechnology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, eye care.

According to a news release, the company’s eye care line will feature refreshed design and improved packaging for Ocucyn Eyelid and Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago, October 18 to 21, 2024.

The companies noted they entered into a distribution agreement in 2021, granting EMC Pharma the exclusive right to manage, market and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the United States.

According to an addendum to the agreement by the partners, EMC Pharma will now additionally have the right to sell over-the-counter Ocucyn, and Sonoma will have the right to sell AcuicynEyelid and Eyelash Cleanser, a prescription product marketed to ophthalmologists.¹

Sonoma will also debut a design and consumer-friendly packaging for Ocucyn, featuring a single-piece dispense mechanism, which allows for more convenient use.

Ocucyn and Acuicyn are hypochlorous acid-based solutions designed to gently cleanse the area surrounding the eye, removing dirt, oil and debris along with microorganisms such as bacteria, fungi and viruses, using the power of Microcyn technology.

The over-the-counter formulation of Ocucyn is used for daily eye hygiene and to relieve itch and irritation. Ocucyn is also used by ophthalmologists before and after eye exams, treatments or operations. Acuicyn provides a prescription-strength formula that ophthalmologists can use in their practice or prescribe to their patients to manage symptoms of chronic eye conditions such as dry eye, contact lens intolerance, blepharitis and meibomian gland dysfunction.¹

In the news release, the companies noted the co-marketing of these products will allow Sonoma and EMC Pharma to provide their customers with additional options for eye care and expand the market reach for each product.

"Eye care has been an area of growth for EMC and we are pleased to expand our partnership with Sonoma, and to expand our product offerings," Eric Bailey, CEO of EMC Pharma, said in the news release. "Ocucyn will provide an over-the-counter option for our existing customers in addition to attracting new eye care customers in our distribution channels which include many government entities."

Amy Trombly, CEO of Sonoma, said the company’s partnership with EMC Pharma has been a success for both companies.

“We are excited to open up new channels for both Sonoma and EMC with this co-marketing agreement. Both companies have invested in marketing eye care products and by coordinating our efforts, we expect to increase sales of both OTC and prescription eye care," she said in the news release.

Ocucyn is available to consumers through the Sonoma website and on Amazon. Products with new packaging can be ordered now for October delivery.

Reference:

1. Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line. ACCESSWIRE Newsroom. Published September 11, 2024. Accessed September 11, 2024. https://www.accesswire.com/915832/sonoma-pharmaceuticals-and-emc-pharma-announce-collaboration-to-co-market-an-expanded-eye-care-product-line